Hester de Groot‐Kruseman

Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group

Rob Pieters, Hester de Groot‐Kruseman, Vincent van der Velden et al. · Journal of Clinical Oncology · 2016 · 370 citations · Full text

Medicine, Oncology, Pediatrics +16

Improved Outcome for ALL by Prolonging Therapy for <i>IKZF1</i> Deletion and Decreasing Therapy for Other Risk Groups

Rob Pieters, Hester de Groot‐Kruseman, Marta Fiocco et al. · Journal of Clinical Oncology · 2023 · 41 citations · Full text

Medicine, Oncology, Chemotherapy +12

Efficacy and safety of recombinant <i>E. coli</i> asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group

Inge M. van der Sluis, Hester de Groot‐Kruseman, D. Maroeska W. M. te Loo et al. · Pediatric Blood & Cancer · 2018 · 22 citations · Full text

Medicine, Oncology, Pediatrics +11

Assessment of Mercaptopurine (6MP) Metabolites and 6MP Metabolic Key-Enzymes in Childhood Acute Lymphoblastic Leukemia

Anna Wojtuszkiewicz, Ana Maria Ferreira Barcelos, Boas Dubbelman et al. · Nucleosides Nucleotides & Nucleic Acids · 2014 · 14 citations

Medicine, Biochemistry, Pharmacology +15

ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?

Anna Østergaard, Marta Fiocco, Hester de Groot‐Kruseman et al. · Leukemia · 2024 · 14 citations · Full text

Medicine, Oncology, Pharmacology +16